viewMountain Valley MD Holdings Inc

Mountain Valley MD adds South African Variant to Bio Safety Level 4 lab study

Mountain Valley MD (CSE: MVMD- OTCQB: MVMDF) Director of Life Scienced Mike Farber joined Steve Darling from Proactive with news the company has announced they are adding the South African Variant to their upcoming Bio Safety Level 4 lab study, which is analyzing viral clearance efficacy with the Company's Ivermectin technology.

Farber talks about why they thought this was an important step to take considering there is concern about the variant whether the vaccines are rendered less effective against the variant.

Quick facts: Mountain Valley MD Holdings Inc

Price: 1.44 CAD

Market: CSE
Market Cap: $359.38 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Mountain Valley MD Holdings Inc named herein, including the promotion by the Company of Mountain Valley MD Holdings Inc in any Content on the...


Mountain Valley MD gets approval for COVID-19 clearance trial in Level 4 Bio...

Mountain Valley MD (CSE: MVMD) CEO Dennis Hancock and Director of Life Sciences Mike Farber joined Steve Darling with news the company will be conducting a Bio-Safety Level 4 lab study of COVID-19 viral clearance to prove out the Company’s solubilized Ivermectin technology versus commercially...

on 01/27/2021

2 min read